×

EVIGATOR 1

What we do 1 What sets us apart 1 Our solutions 1 What we think 1
×

Global RWE 2

What we do 2 What sets us apart 2 Our solutions 2 What we think 2
×

Strategic Services 3

What we do 3 What sets us apart 3 Our solutions 3 What we think 3
0
Skip to Content
GIPAM
Why GIPAM
About
Corporate Responsibility
Careers
Services
Strategic Services
Global RWE
Evidence Synthesis
ANCHOR
ONCOCASE
EVIGATOR
Insights
News
Whitepapers & Publications
Events & Webinars
Ask me about RWE
Contact
Subscribe to Newsletter
Shop
GIPAM
Why GIPAM
About
Corporate Responsibility
Careers
Services
Strategic Services
Global RWE
Evidence Synthesis
ANCHOR
ONCOCASE
EVIGATOR
Insights
News
Whitepapers & Publications
Events & Webinars
Ask me about RWE
Contact
Subscribe to Newsletter
Shop
Folder: Why GIPAM
Folder: Services
Folder: Insights
Contact
Subscribe to Newsletter
Shop
Back
About
Corporate Responsibility
Careers
Back
Strategic Services
Global RWE
Evidence Synthesis
ANCHOR
ONCOCASE
EVIGATOR
Back
News
Whitepapers & Publications
Events & Webinars
Ask me about RWE
Shop Early network meta-analysis (NMA) feasibility assessment
Back
Online Shop images-1-Consulation .png Image 1 of
Online Shop images-1-Consulation .png

Early network meta-analysis (NMA) feasibility assessment

€25,700.00

An early NMA feasibility assessment to plan for future indirect treatment comparisons

Designed for: Internal teams planning future indirect treatment comparisons.

Scope: Early feasibility assessment to determine if available evidence supports an NMA.

Add-on: Conducted following completion of a targeted literature review (TLR).

Process: network diagram generation; assessment of homogeneity; evaluation of data availability; and tailored NMA recommendations.

Output: Concise summary slide deck (MS PPT [30 slides]), outlining feasibility, limitations, and next steps for an NMA.

Timeline: 3 weeks

Quantity:
Add To Cart

An early NMA feasibility assessment to plan for future indirect treatment comparisons

Designed for: Internal teams planning future indirect treatment comparisons.

Scope: Early feasibility assessment to determine if available evidence supports an NMA.

Add-on: Conducted following completion of a targeted literature review (TLR).

Process: network diagram generation; assessment of homogeneity; evaluation of data availability; and tailored NMA recommendations.

Output: Concise summary slide deck (MS PPT [30 slides]), outlining feasibility, limitations, and next steps for an NMA.

Timeline: 3 weeks

An early NMA feasibility assessment to plan for future indirect treatment comparisons

Designed for: Internal teams planning future indirect treatment comparisons.

Scope: Early feasibility assessment to determine if available evidence supports an NMA.

Add-on: Conducted following completion of a targeted literature review (TLR).

Process: network diagram generation; assessment of homogeneity; evaluation of data availability; and tailored NMA recommendations.

Output: Concise summary slide deck (MS PPT [30 slides]), outlining feasibility, limitations, and next steps for an NMA.

Timeline: 3 weeks

You Might Also Like

Targeted Literature Review (TLR) [medium]
Targeted Literature Review (TLR) [medium]
€76,800.00
Targeted Literature Review (TLR) [small]
Targeted Literature Review (TLR) [small]
€50,133.00
Automated data extraction tables
Automated data extraction tables
€9,800.00
SLR on Clinical Efficacy for Health Technology Assessments
SLR on Clinical Efficacy for Health Technology Assessments
€168,252.00
Automated study listing
Automated study listing
€5,700.00

Do you have questions?

CONTACT US >

Contact Us

GIPAM GmbH

Alter Holzhafen 19

23966 Wismar, Germany

Phone: +49 3841 758 1014

info@gipam-health.com

Shop Form
Please provide your contact details and we will contact you about your wishlist
Name *

Thank you for your submission.

As you’ll likely need a full contract, we’ll send you a draft within the next 48 working hours. Once received, please review the draft carefully. If you're happy to proceed, you can either sign it directly or let us know if you’d prefer to use an electronic signature process.

Should you have any feedback or request changes, we’re happy to consider them—please email Sabrina at sabrina.mueller@gipam-health.com.

Once the contract is signed, our project manager will be in touch right away to schedule your kick-off meeting.

Our Services

Strategic Services

Global RWE

Evidence Synthesis

Ask me about RWE

Learn more

News & Seminars

Whitepapers & Publications

About Us

Corporate Responsibility

Code of Conduct

Privacy Policy

Cookie Policy

Terms of Use

Connect

Can we help?
Online Shop images-1-Consulation .png